Purpose: Neuroblastoma is the most frequent extracranial solid tumors in infants, with a characteristic presentation and a possibility of spontaneous regression even in disseminated disease. Despite an overall good prognosis, relapse can occur in some patients, leading to a poorer outcome in a subgroup of patients. A long-term analysis of these patients assessing survival at 10 years from diagnosis is relevant in estimating the risks of late relapse, progression or long-term toxicity due to very young exposure to treatment. Methods: Estimation of the 10-year event-free and overall survivals in 750 infants under 12 months of age with Neuroblastoma, enrolled in the prospective INES protocols between 1999 and 2004. Follow-up data from INES patients were updated, and survival analyses were performed in order to determine prognostic factors such as: age, stage, genomic profile or MYCN amplification. Results: Overall, 10-year OS was 91.1% ± 1.0%, and 10-year EFS was 82.4% ±1.4%, with significantly better outcomes in infants under 6 months compared to those aged 6 to 12 months, even considering the MYCN-amplified tumors only. MYCN amplification was the strongest prognostic factor and was correlated with substantially lower survival rates among patients with metastatic disease. Discussion: Survival in infancy remains excellent and stable even at long term, as a 10-year follow-up did not change the number of events. However, survival in MYCN-amplified tumors remained poor, this population needs to be treated more aggressively. Patients with metastatic tumors require accurate risk stratification, especially for younger infants under 6 months. For each treatment group, there was no significant difference in long-term outcomes compared to previous publications from INES. No lethal toxicity affecting long-term survival occurred.